Metabasis (MBRX) To Receive $6M Fee From Merck, But Still Warns About Its Future

June 10, 2009 4:35 PM EDT

Metabasis Therapeutics, Inc. (Nasdaq: MBRX) announced that its four year research collaboration with Merck & Co., Inc. (NYSE: MRK), focused on the discovery and development of AMP protein kinase (AMPK) activators, has yielded a lead candidate that Merck has selected to advance into late preclinical development.

In addition, under an amended agreement, Merck has agreed to pay Metabasis a one-time fee of $6 million that satisfies all future obligations for milestones and royalty payments.

Metabasis warned that even with the $6 million payment described above, if the Company is unsuccessful in the near-term in raising additional capital, the Company may be forced to cease its operations entirely.

Related Categories

Corporate News
FDA

Stocks Mentioned

Add Your Comment

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?